This content is from: Portfolio AbbVie Enters the Battle of the Biosimilars Pharmaceuticals giant AbbVie is fighting to protect its blockbuster biologic Humira from challenges by lower-price competitors. By Khadijah M. Silver January 15, 2016
This content is from: Corner Office John Paulson on Playing Today’s M&A Game The founder of Paulson & Co. has been doing merger arb for years. At Delivering Alpha he offers a tutorial on the current, booming M&A scene. By Robert Teitelman July 16, 2014
This content is from: Portfolio Daily Agenda: Investors Play the ECB Waiting Game AbbVie acquires Pharmacyclics; China lowers growth targets; Federal Reserve releasing stress test results. By Andrew Barber March 05, 2015
This content is from: Portfolio The Morning Brief: Hedge Funds Report Gains in July By Amanda Cantrell August 08, 2016
This content is from: Research The 2013 All-America Research Team: Pharmaceuticals/Major, No. 3: David Risinger Slipping one position to third place is Morgan Stanley’s David Risinger, who also earns a runner-up spot in Pharmaceuticals/Specialty. By Leslie Kramer October 08, 2013
This content is from: Portfolio Aggressive Pharma Ads Yield Results — and Complaints Drugmakers such as AbbVie and Valeant have been able to boost sales through direct-to-consumer advertising, but at what cost? By Khadijah M. Silver December 04, 2015
